skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Insulin therapy in critically ill patients

Review

(2136) Views  (955) Full article downloads

Authors: Samer Ellahham

Published Date December 2010 Volume 2010:6 Pages 1089 - 1101
DOI: http://dx.doi.org/10.2147/VHRM.S14203

Samer Ellahham
Samer Ellahham and Associates, Falls Church, VA, USA

Abstract: Hyperglycemia frequently occurs with acute medical illness, especially among patients with cardiovascular disease, and has been linked to increased morbidity and mortality in critically ill patients. Even patients who are normoglycemic can develop hyperglycemia in response to acute metabolic stress. An expanding body of literature describes the benefits of normalizing hyperglycemia with insulin therapy in hospitalized patients. As a result, both the American Diabetes Association and the American College of Endocrinology have developed guidelines for optimal control of hyperglycemia, specifically targeting critically ill, hospitalized patients. Conventional blood glucose values of 140–180 mg/dL are considered desirable and safely achievable in most patients. More aggressive control to <110 mg/dL remains controversial, but has shown benefits in certain patients, such as those in surgical intensive care. Intravenous infusion is often used for initial insulin administration, which can then be transitioned to subcutaneous insulin therapy in those patients who require continued insulin maintenance. This article reviews the data establishing the link between hyperglycemia and its risks of morbidity and mortality, and describes strategies that have proven effective in maintaining glycemic control in high-risk hospitalized patients.

Keywords: hyperglycemia, cardiovascular disease, insulin, intensive care, critical care






Readers of this article also read:

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Impact of a diabetic foot care education program on lower limb amputation rate
Prognostic value of changes in arterial stiffness in men with coronary artery disease
Optimal management of familial hypercholesterolemia: treatment and management strategies
Inhaled treprostinil and pulmonary arterial hypertension
Stent-grafts in the management of life-threatening hemorrhage following inadvertent femoral catheterization in high-risk patients: report of two cases and review of the literature
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University